載入...
Chemotherapy re-challenge response rate in metastatic colorectal cancer
BACKGROUND: There are few treatment options in metastatic colorectal cancer (mCRC) after progression on standard chemotherapy. Third and fourth line therapies typically consist of regorafenib or trifluridine-tipiracil, however, clinical benefit of these medications is limited, as progression free su...
Na minha lista:
| 發表在: | J Gastrointest Oncol |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AME Publishing Company
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6087874/ https://ncbi.nlm.nih.gov/pubmed/30151264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2018.04.08 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|